Richard Yaple
Internal Medicine · Salina, KSNPI 1730187329
Payments from drug & device makers
Across 109 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$223
- Johnson & Johnson$204
- Amgen$192
- Lilly USA, LLC$171
- Astellas Pharma US Inc$125
- Novo Nordisk$122
- plus $635 from 17 others
What the payments were for
- Food & beverage$1,65899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $223 |
| Johnson & Johnson | 13 | $204 |
| Amgen | 15 | $192 |
| Lilly USA, LLC | 12 | $171 |
| Astellas Pharma US Inc | 10 | $125 |
| Novo Nordisk | 8 | $122 |
| Novartis | 7 | $104 |
| Bayer | 2 | $92 |
| AstraZeneca | 6 | $86 |
| Sanofi-aventis U.S. LLC | 6 | $81 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| AbbVie | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Mylan Specialty L.p. | 1 | $11 |
| GSK | 1 | $11 |
How this compares
$1,672 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $24,904 |
| TrulicityDulaglutide | 16 | $16,482 |
| MyrbetriqMirabegron | 29 | $9,366 |
| JardianceEmpagliflozin | 13 | $3,822 |
| Novolog FlexpenInsulin Aspart | 17 | $1,601 |
| Pregabalin | 12 | $1,418 |
| Levothyroxine Sodium | 90 | $1,146 |
| Mirtazapine | 17 | $408 |
| Trospium Chloride | 12 | $304 |
| Atorvastatin Calcium | 40 | $262 |
| Gabapentin | 28 | $250 |
| Metoprolol Succinate | 20 | $186 |
| Lactulose | 14 | $175 |
| Amlodipine Besylate | 29 | $171 |
| Ondansetron Hcl | 11 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $24,90429 claims |
| Lilly USA, LLCTrulicity | $171 | $16,48216 claims |
| Astellas Pharma US IncMyrbetriq | $125 | $9,36629 claims |
| Boehringer IngelheimJardiance | $17 | $3,82213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Salina
- Cameron Petro-SakurSalina$5K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.